Items Tagged ‘General Renal Cancer’

December 5th, 2016

Cabometyx™ Improves Time to Cancer Progression as Initial Therapy in Kidney Cancer

By

The agent Cabometyx™ (cabozantinib) improves anti-cancer responses and time to cancer progression compared to Sutent® (sunitinib) when used as initial therapy for advanced kidney cancer. These results were recently published in the Journal of Clinical Oncology. The kidneys are a pair of organs with multiple functions. Renal cell carcinoma is the most common type of […]

View full entry

Tags: AXL, Cabometyx, cabozantinib, General Renal Cancer, kidney cancer, MET, metastatic, mRCC, News, Renal Cancer, sunitinib, Sutent


May 24th, 2016

Lenvima® Approved for Kidney Cancer

By

The United States Food and Drug Administration (FDA) has approved Lenvima® (lenvatinib) for the treatment of kidney cancer. The approval is for patients with advanced renal cell carcinoma who have received at least one prior therapy with an anti-angiogenic agent, and is to be used in combination with the standard agent Afinitor® (everolimus). Each year […]

View full entry

Tags: afinitor, everolimus, fda, General Renal Cancer, kidney cancer, lenvatinib, Lenvima, News, rcc, Renal Cancer, RTK


May 10th, 2016

Cabometyx® Approved for Kidney Cancer

By

The United States Food and Drug Administration (FDA) has approved the kinase inhibitor Cabometyx (cabozantinib) for the treatment of renal cell carcinoma (kidney cancer). The approval is for patients with advanced renal cell carcinoma who have already been treated with prior anti-angiogenic therapy. Each year in the United States, more than 61,000 people are diagnosed […]

View full entry

Tags: Cabometyx, cabozantinib, General Renal Cancer, kidney cancer, kinase inhibitor, metastatic, News, rcc, Renal Cancer, renal cell carcinoma


March 15th, 2016

Clinical Study Evaluating Dalantercept in Combination with Axitinib Now Enrolling Advanced RCC Patients Nationwide

By

If you are battling kidney cancer, otherwise known as renal cell carcinoma (RCC), The DART Study may be the next treatment option for you to consider. Dalantercept, in combination with axitinib, an FDA approved therapy, aims to halt the growth and spread of RCC. The DART Study is testing the safety and efficacy of dalantercept in combination with axitinib and is […]

View full entry

Tags: axitinib, clinical trial, dalantercept, DART study, General Renal Cancer, kidney cancer, News, rcc, Renal Cancer, renal cell carcinoma, study


November 25th, 2015

FDA Approves Opdivo for Renal Cell Carcinoma

By

The FDA granted approval to nivolumab (Opdivo) for patients with renal cell carcinoma. Opdivo, a PD-1 inhibitor, was previously approved for the treatment of melanoma whose tumors express the BRAF V600 mutation as well as advanced non-small cell lung cancer. About Renal Cell Carcinoma Each year in the United States, more than 61,000 people are […]

View full entry

Tags: General Renal Cancer, kidney cancer, News, nivolumab, opdivo, rcc, Renal Cancer, renal cell cancer


October 15th, 2015

COMETRIQ® Improves Progression-Free Survival in Kidney Cancer

By

According to a recently published study in the New England Journal of Medicine, the targeted agent, COMETRIQ® (cabozantinib), significantly improves the time to cancer progression and survival compared to Afinitor® (everolimus) in patients with advanced kidney cancer whose cancer has progressed following VEGRF-targeted therapy. Each year in the United States, more than 58,000 people are […]

View full entry

Tags: afinitor, cabozantinib, COMETRIQ, General Renal Cancer, kidney cancer, News, rcc, Renal Cancer, VEGFR-targeted agents


July 29th, 2015

Study of Opdivo® versus Afinitor® Stopped Early when Opdivo Demonstrated Better Survival

By

Patients with advanced or metastatic kidney cancer who are treated with Opdivo® (nivolumab) have better overall survival than those treated with Afinitor® (everolimus), according to findings from a Phase III clinical trial. Because the improved survival with Opdivo was apparent sooner than expected, the trial has been stopped early. Each year in the United States, […]

View full entry

Tags: General Renal Cancer, kidney cancer, News, nivolumab, opdivo, rcc, Renal Cancer, renal cell carcinoma


June 9th, 2014

Data Demonstrates Benefit of Utilizing Multiple Biological Pathways to Predict Tumor Behavior in Prostate and Renal Cancers

By

REDWOOD CITY, Calif., June 3, 2014 /PRNewswire/ – Genomic Health, Inc. (Nasdaq: GHDX) today announced results of two studies demonstrating the ability of its Oncotype DX® test and a new 16-gene panel to predict disease aggressiveness and clinical outcomes in prostate and renal cancers, respectively. These results, presented at the American Society of Clinical Oncology® (ASCO®) Annual […]

View full entry

Tags: Early Stage I-II (A-B) Prostate Cancer, General Renal Cancer, genomic testing, kidney cancer, News, oncotype, Prostate Cancer, Renal Cancer


October 8th, 2012

New Treatment Options for Advanced Renal Cell Carcinoma

By

The results from three phase III trials shed new light on treatment options for patients with advanced renal cell carcinoma. The studies were presented at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna. More than 58,000 people are diagnosed with kidney cancer in the United States each year. The most […]

View full entry

Tags: General Renal Cancer, News, Renal Cancer


June 11th, 2012

PD-1 Targeted Immune Therapy Shows Promising Activity

By

The investigational drug BMS-936558 caused tumor shrinkage in nearly 25 percent of patients with advanced melanoma, kidney cancer and non-small cell lung cancer (NSCLC), according to the results of a phase I study presented at the 2012 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois. BMS-936558 is a targeted immune […]

View full entry

Tags: General Renal Cancer, Lung Cancer - Non-Small Cell, Melanoma, News, Recurrent Lung Cancer - Non-Small Cell, Recurrent Melanoma, Renal Cancer, Stage IV Melanoma, Urology


April 27th, 2012

Partial Nephrectomy is Associated with Improved Survival in Early Stage Kidney Cancer

By

Patients with early stage kidney cancer who had only the tumor removed experienced better survival rates than those who had the entire kidney removed, according to the results of a study published in the Journal of the American Medical Association.[1] Nearly 65,000 people are diagnosed with kidney cancer in the United States each year. For […]

View full entry

Tags: General Renal Cancer, News, Renal Cancer, Urology


April 23rd, 2012

Tivozanib Promising for Metastatic Renal Cell Carcinoma

By

Tivozanib (AV-951) was well tolerated and improved median progression-free survival (PFS) in some patients with advanced renal cell carcinoma (RCC), according to the results of a phase II study published in the Journal of Clinical Oncology. More than 58,000 people are diagnosed with kidney cancer in the United States each year. The most common type […]

View full entry

Tags: General Renal Cancer, News, Renal Cancer, Urology


March 26th, 2012

Aspirin Continues to Look Promising for Cancer Prevention

By

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce the risk of several types of cancer, with particularly strong evidence […]

View full entry

Tags: Anal Cancer, Bladder Cancer, Bone Cancer, Brain Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Esophageal Cancer, Gastric Cancer, General Bone Cancer, General Brain Cancer, General Head and Neck Cancer


February 28th, 2012

Targeted Drugs Produce Complete Responses in Some Patients with Metastatic Kidney Cancer

By

Some patients with metastatic kidney cancer experience a complete response (a complete disappearance of detectable cancer) after treatment with Sutent® (sunitinib) or Nexavar® (sorafenib), but researchers have not yet been able to predict which patients are most likely to achieve this level of response. These results were published in the Journal of Clinical Oncology. Each […]

View full entry

Tags: General Renal Cancer, News, Renal Cancer, Urology


February 17th, 2012

Lynch Syndrome Also Linked with Breast and Pancreatic Cancer

By

A study of families with Lynch Syndrome has expanded the list of cancers related to the condition: carriers of a Lynch Syndrome gene mutation also appear to have an increased risk of breast cancer and pancreatic cancer. These results were published in the Journal of Clinical Oncology. Lynch Syndrome, also known as hereditary nonpolyposis colorectal […]

View full entry

Tags: Bladder Cancer, Breast Cancer, Colon Cancer, Gastric Cancer, General Renal Cancer, General Retinoblastoma, HBOC, News, Ovarian Cancer, Pancreatic Cancer, Rectal Cancer, Renal Cancer